🇺🇸 FDA
Patent

US 8486370

Heterocyclic ligands for integrin imaging and therapy

granted A61KA61K51/0453A61K51/0455

Quick answer

US patent 8486370 (Heterocyclic ligands for integrin imaging and therapy) held by The Regents of the University of California expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
49
CPC classes
A61K, A61K51/0453, A61K51/0455, A61K51/0459, A61K9/0014